Bharat Immunologicals Share Price | Bharat Immunologicals Stock Screener
BIBCL
Pharmaceuticals
Share Price BSE
₹17.73
▲
0.39 (2.25%)
As of May 27, 2026, the Bharat Immunologicals share price (BSE: BIBCL) is ₹17.73, up 2.25% from the previous close, with shares trading between ₹17.34 and ₹17.90, and a 52-week range of ₹14.25–₹26.77.
Check BIBCL 52-week performance for the annual price range and momentum.
Use the Bharat Immunologicals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Bharat Immunologicals Market Cap
₹75.82 Cr.
BIBCL P/E Ratio (TTM)
-4.19
Bharat Immunologicals P/B Ratio
-2.32
EPS (TTM)
₹-3.95
Dividend Yield
-
Debt to Equity
-
BIBCL 52 Week High
₹26.77
Bharat Immunologicals 52 Week Low
₹14.25
Operating Margin
-13.00%
Profit Margin
-200.00%
BIBCL Revenue (TTM)
₹9.00
EBITDA
₹-17.00
Net Income
₹-18.00
Total Assets
₹186.00
Total Equity
₹88.00
Bharat Immunologicals Share Price Chart
Screen Bharat Immunologicals share price with an interactive chart. Analyse BIBCL price trends and volatility across different timeframes.
Bharat Immunologicals Company Profile - Fundamental Screener
Screen Bharat Immunologicals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BIBCL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE994B01014
Bharat Immunologicals Balance Sheet Screener
Screen BIBCL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total Assets | 186 | 213 | 104 | 127 | 125 | 53 | 59 | 68 | 80 |
| Current Assets | 33 | 65 | 34 | 93 | 99 | 38 | 47 | 60 | 74 |
| Fixed Assets | 115 | 116 | 4 | 5 | 5 | 5 | 5 | 6 | 6 |
| Liabilities | |||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 6 | 6 | 6 | 6 | 6 | 3 | 3 | 3 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||||
| Total Equity | 88 | 105 | 34 | 21 | 31 | 38 | 42 | 35 | 41 |
| Share Capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| Reserves & Surplus | 45 | 62 | -9 | -23 | -13 | -6 | -1 | -8 | -2 |
Bharat Immunologicals Income Statement Screener - Profit & Revenue Analysis
Screen Bharat Immunologicals income statement and profit fundamentals.
Analyze BIBCL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Bharat Immunologicals share price evaluation.
| Item | None-None | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 47 | 80 | 87 | 68 | 88 | 36 | 125 | 129 | 147 |
| Expenses | 25 | 63 | 83 | 106 | 77 | 93 | 43 | 112 | 133 | 143 |
| EBITDA | -17 | -16 | -4 | -19 | -9 | -5 | -7 | 14 | -4 | 4 |
| Operating Profit % | -13.00% | -41.00% | -6.00% | -24.00% | -16.00% | -11.00% | -24.00% | 10.00% | -4.00% | 2.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Interest | 8 | 7 | 6 | 5 | 5 | 2 | 1 | 4 | 5 | 1 |
| Profit Before Tax | -25 | -23 | -10 | -24 | -14 | -7 | -8 | 9 | -9 | 2 |
| Tax | 0 | -6 | -1 | -6 | -4 | -2 | -4 | 3 | -3 | 1 |
| Net Profit | -18 | -17 | -9 | -18 | -10 | -6 | -4 | 7 | -6 | 2 |
| EPS | -4.20 | -3.95 | -2.03 | 1.10 | -2.36 | -1.34 | -0.99 | 1.51 | -1.44 | 0.36 |
Bharat Immunologicals Cash Flow Screener - Liquidity Fundamentals
Screen BIBCL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 11 | -42 | 12 | 34 | -32 | 3 | -17 | -9 | 8 |
| Investing Activities | 1 | 1 | 1 | 1 | 1 | -1 | 1 | 1 | 0 |
| Financing Activities | -15 | 45 | -12 | -34 | 31 | -1 | -3 | -2 | -1 |
| Net Cash Flow | -3 | 3 | 0 | 1 | -1 | 1 | -20 | -10 | 7 |
Bharat Immunologicals Shareholding Pattern Screener
See Bharat Immunologicals shareholding pattern with promoter, FII, and DII holdings.
Check Bharat Immunologicals promoter holding and ownership changes for BIBCL on TickJournal.
| Item | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% | 59.25% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 39.47% | 39.35% | 39.30% | 39.13% | 38.97% | 38.86% | 39.11% | 39.15% |
| Other Holding | 1.28% | 1.39% | 1.45% | 1.61% | 1.77% | 1.88% | 1.63% | 1.59% |
| Shareholder Count | 35,313 | 34,910 | 34,201 | 34,818 | 35,535 | 36,242 | 35,411 | 35,695 |
Bharat Immunologicals Share Dividend Screener - Share Yield Analysis
Check Bharat Immunologicals dividend history with payout and yield data.
View Bharat Immunologicals dividend details including ex-dates and amounts for BIBCL stock.
Bharat Immunologicals Stock Index Membership
See which indices include Bharat Immunologicals stock.
Check BIBCL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX CPSE
Bharat Immunologicals Market Events Screener - Corporate Actions
Get Bharat Immunologicals corporate actions including splits, bonuses, and buybacks.
Check Bharat Immunologicals stock events that may affect BIBCL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2023-12-29 | 2023-12-29 | Annual General Meeting | NA | 39.59% |
Bharat Immunologicals Competitors Screener - Peer Comparison
Screen BIBCL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,581 | 41.43 | 54,729 | 9.71% | 10,980 | 54.75 |
| Divis Laboratories | 182,828 | 73.47 | 9,712 | 18.67% | 2,191 | 66.48 |
| Torrent Pharmaceuticals | 151,833 | 66.60 | 11,539 | 6.99% | 1,911 | 61.90 |
| Cipla | 113,025 | 29.32 | 27,712 | -2.46% | 3,783 | 61.92 |
| Dr Reddys Laboratories | 109,105 | 26.47 | 33,593 | -0.44% | 3,998 | 52.61 |
| Zydus Life Science | 104,543 | 20.35 | 26,720 | 13.65% | 5,242 | 69.40 |
| Lupin | 104,288 | 19.51 | 27,488 | 19.98% | 5,345 | 47.33 |
| Mankind Pharma | 102,351 | 53.58 | 14,278 | 12.03% | 1,750 | 62.34 |
| Aurobindo Pharma | 85,000 | 25.77 | 32,346 | 9.43% | 3,484 | 52.91 |
| Laurus Labs | 72,530 | 81.91 | 6,813 | 21.03% | 884 | 77.10 |
Bharat Immunologicals Company Announcements - News Screener
Screen BIBCL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2024-08-07 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 16.08.2024 Under Regulation 29 Of SEBI'S LODR. | - |
| 2024-02-29 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 08.03.2024 Under Regulation 29 Of SEBI'S LODR. | - |
| 2023-12-13 | Compliance Of Regulation 34 Of LODR 2015 And Submission Annual Report For 34Th Annual General Meeting Scheduled On 29.12.2023. | - |
| 2023-11-28 | Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (22.12.2023 To 29.12.2023) Of The Company In Respect Of 34Th Annual General Meeting Scheduled To Be Held On 29.12.2023. | - |
| 2023-11-28 | Submission Of Notice Of 34Th Annual General Meeting On 29.12.2023 As Compliance Of The Provision Of LODR 2015. | - |
| 2023-11-01 | Submission Of Unaudited Quarterly Financial Results Alongwith Limited Review Report For The Quarter And Half Year Ended September 2023 As Compliance Of LODR 2015 | - |
| 2023-11-01 | Submission Of Unaudited Quarterly Financial Results Alongwith Limited Review Report For The Quarter Ended June 2023 As Compliance Of LODR 2015 | - |
| 2023-10-19 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 31St October 2023 Under Regulation 29 Of SEBI'S LODR. | - |
| 2023-09-15 | Submission Of Signed Audited Annual Accounts 2022-23 Alongwith Statutory Audit Report Thereof Provided By The Statutory Auditor Appointed By Comptroller & Auditor General Of India (C&AG). | - |
| 2023-05-31 | Submission Of Annual Accounts For The Financial Year Ended On 31.03.2023 And Is Under Audit Of Statutory Auditor Appointed By C&AG | - |
| 2023-05-10 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2023-05-10 | Compliance Certificate Under Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ending On 31.03.2023. | - |
| 2023-04-27 | Certificate From Practicing Company Secretary Under Regulation 40 (9) Of SEBI (LODR) Regulations 2015 For The Year Ended 31.03.2023 | - |
| 2023-04-17 | Update on board meeting | - |
| 2023-04-17 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 17Th April 2023 Under Regulation 29 Of SEBI'S LODR. | - |
| 2023-02-10 | Submission Of Unaudited Quarterly Financial Results For The Quarter And Nine Months Ended December 2022 Along With Limited Review Report | - |
| 2023-02-01 | Board Meeting Intimation for Intimation Of Date Of Board Meeting On 09Th February 2023 Under Regulation 29 Of SEBI'S LODR. | - |
| 2022-12-27 | Clarification sought from Bharat Immunologicals & Biologicals Corporation Ltd | - |
| 2022-10-17 | Board Meeting Outcome for Submission Of Un-Audited Quarterly Financial Results For The Quarter Ended September 2022 And Limited Review Report Thereon As Per The Compliance Of LODR 2015 | - |
| 2022-10-11 | Statement Of Investor Complaints For The Quarter Ended September 2022 | - |